Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Garcinia mangostana Linn., commonly known as mangosteen, is a tropical fruit with a thick pericarp rind containing bioactive compounds that may be beneficial as an adjunctive treatment for schizophrenia. The biological underpinnings of schizophrenia are believed to involve altered neurotransmission, inflammation, redox systems, mitochondrial dysfunction, and neurogenesis. Mangosteen pericarp contains xanthones which may target these biological pathways and improve symptoms; this is supported by preclinical evidence. Here we outline the protocol for a double- blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp (1,000 mg/day), compared to placebo, in the treatment of schizophrenia. Methods: We aim to recruit 150 participants across two sites (Geelong and Brisbane). Participants diagnosed with schizophrenia or schizoaffective disorder will be randomized to receive 24 weeks of either adjunctive 1,000 mg/day of mangosteen pericarp or matched placebo, in addition to their usual treatment. The primary outcome measure is mean change in the Positive and Negative Symptom Scale (total score) over the 24 weeks. Secondary outcomes include positive and negative symptoms, general psychopathology, clinical global severity and improvement, depressive symptoms, life satisfaction, functioning, participants reported overall improvement, substance use, cognition, safety and biological data. A 4-week post treatment interview at week 28 will explore post-discontinuations effects. Results: Ethical and governance approvals were gained and the trial commenced. Conclusion: A positive finding in this study has the potential to provide a new adjunctive treatment option for people with schizophrenia and schizoaffective disorder. It may also lead to a greater understanding of the pathophysiology of the disorder.
Abstract
Objective: Garcinia mangostana Linn., commonly known as mangosteen, is a tropical fruit with a thick pericarp rind containing bioactive compounds that may be beneficial as an adjunctive treatment for schizophrenia. The biological underpinnings of schizophrenia are believed to involve altered neurotransmission, inflammation, redox systems, mitochondrial dysfunction, and neurogenesis. Mangosteen pericarp contains xanthones which may target these biological pathways and improve symptoms; this is supported by preclinical evidence. Here we outline the protocol for a double- blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp (1,000 mg/day), compared to placebo, in the treatment of schizophrenia. Methods: We aim to recruit 150 participants across two sites (Geelong and Brisbane). Participants diagnosed with schizophrenia or schizoaffective disorder will be randomized to receive 24 weeks of either adjunctive 1,000 mg/day of mangosteen pericarp or matched placebo, in addition to their usual treatment. The primary outcome measure is mean change in the Positive and Negative Symptom Scale (total score) over the 24 weeks. Secondary outcomes include positive and negative symptoms, general psychopathology, clinical global severity and improvement, depressive symptoms, life satisfaction, functioning, participants reported overall improvement, substance use, cognition, safety and biological data. A 4-week post treatment interview at week 28 will explore post-discontinuations effects. Results: Ethical and governance approvals were gained and the trial commenced. Conclusion: A positive finding in this study has the potential to provide a new adjunctive treatment option for people with schizophrenia and schizoaffective disorder. It may also lead to a greater understanding of the pathophysiology of the disorder.
참고문헌 (62)
- Ferrari AJ, "Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 study", Popul Health Metr, 10, pp.16~ (2012)
- Miyamoto S, "Treatments for schizophrenia : a critical review of pharmacology and mechanisms of action of antipsychotic drugs", Mol Psychiatry, 10, pp.79~104 (2005)
- Dean OM, "A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice", Curr Med Chem, 16, pp.2965~2976 (2009)
- Flatow J, "Meta-analysis of oxidative stress in schizophrenia", Biol Psychiatry, 74, pp.400~409 (2013)
- Ng F, "Oxidative stress in psychiatric disorders : evidence base and therapeutic implications", Int J Neuropsychopharmacol, 11, pp.851~876 (2008)
- Leboyer M, "Immuno-psychiatry : an agenda for clinical practice and innovative research", BMC Med, 14, pp.173~ (2016)
- Davis J, "A review of vulnerability and risks for schizophrenia : beyond the two hit hypothesis", Neurosci Biobehav Rev, 65, pp.185~194 (2016)
- Magalhães PV, "Antioxidant treatments for schizophrenia", Cochrane Database Syst Rev, 2, pp.CD008919~ (2016)
- Wood SJ, "Neurobiology of schizophrenia spectrum disorders : the role of oxidative stress", Ann Acad Med Singapore, 38, pp.396~401 (2009)
- Berk M, "N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial", Biological Psychiatry, 64, pp.361~368 (2008)
- Farokhnia M, "N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia : a randomized, double-blind, placebo-controlled study", Clin Neuropharmacol, 36, pp.185~192 (2013)
- Deepmala, "Clinical trials of N-acetylcysteine in psychiatry and neurology : a systematic review", Neurosci Biobehav Rev, 55, pp.294~321 (2015)
- Rossell SL, "N-acetylcysteine(NAC)in schizophrenia resistant to clozapine : a double blind randomised placebo controlled trial targeting negative symptoms", BMC Psychiatry, 16, pp.320~ (2016)
- Goldsmith DR, "A meta-analysis of blood cytokine network alterations in psychiatric patients : comparisons between schizophrenia, bipolar disorder and depression", Mol Psychiatry, 21, pp.1696~1709 (2016)
- Müller N, "Immunological aspects of the treatment of depression and schizophrenia", Dialogues Clin Neurosci, 19, pp.55~63 (2017)
- Sommer IE, "Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia : an update", Schizophr Bull, 40, pp.181~191 (2014)
- Flippo KH, "An emerging role for mitochondrial dynamics in schizophrenia", Schizophr Res, 187, pp.26~32 (2017)
- Konradi C, "Role of mitochondria and energy metabolism in schizophrenia and psychotic disorders", Schizophr Res, 187, pp.1~2 (2017)
- Rajasekaran A, "Mitochondrial dysfunction in schizophrenia : pathways, mechanisms and implications", Neurosci Biobehav Rev, 48, pp.10~21 (2015)
- Roberts RC, "Postmortem studies on mitochondria in schizophrenia", Schizophr Res, 187, pp.17~25 (2017)
- Inuwa IM, "QSAR modeling and transmission electron microscopy stereology of altered mitochondrial ultrastructure of white blood cells in patients diagnosed as schizophrenic and treated with antipsychotic drugs", Biotech Histochem, 80, pp.133~137 (2005)
- Uranova N, "The ultrastructure of lymphocytes in schizophrenia", World J Biol Psychiatry, 8, pp.30~37 (2007)
- Pereira C, "Mitochondrial agents for bipolar disorder", Int J Neuropsychopharmacol, 21, pp.550~569 (2018)
- 김용구, "Neuroprotection in Schizophrenia and Its Therapeutic Implications", PSYCHIATRY INVESTIGATION, 14(4), pp.383~391 (2017), 대한신경정신의학회[DOI]
- Allen KM, "Cell proliferation is reduced in the hippocampus in schizophrenia", Aust N Z J Psychiatry, 50, pp.473~480 (2016)
- Reif A, "Neural stem cell proliferation is decreased in schizophrenia, but not in depression", Mol Psychiatry, 11, pp.514~522 (2006)
- Inta D, "Microglia activation and schizophrenia : lessons from the effects of minocycline on postnatal neurogenesis, neuronal survival and synaptic pruning", Schizophr Bull, 43, pp.493~496 (2017)
- Chikama K, "Chronic atypical antipsychotics, but not haloperidol, increase neurogenesis in the hippocampus of adult mouse", Brain Res, 1676, pp.77~82 (2017)
- Halim ND, "Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus", Neuropsychopharmacology, 29, pp.1063~1069 (2004)
- Morris G, "Cell death pathways : a novel therapeutic approach for neuroscientists", Mol Neurobiol, 55, pp.5767~5786 (2018)
- Boiadzhian AS, "Markers of apoptotic dysfunction in schizophrenia", Mol Biol, 47, pp.674~680 (2013)
- Tsai MC, "Bcl-2 associated with positive symptoms of schizophrenic patients in an acute phase", Psychiatry Res, 210, pp.735~738 (2013)
- Ferreira AS, "Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia : increment by olanzapine treatment", Eur Arch Psychiatry Clin Neurosci, 265, pp.167~170 (2015)
- Pedraza-Chaverri J, "Medicinal properties of mangosteen(Garcinia mangostana)", Food Chem Toxicol, 46, pp.3227~3239 (2008)
- Funk AJ, "Abnormal activity of the MAPK-and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia", Neuropsychopharmacology, 37, pp.896~905 (2012)
- Ni X, "Human p53 tumor suppressor gene(TP53)and schizophrenia : case-control and family studies", Neurosci Lett, 388, pp.173~178 (2005)
- Pereira A, "Clozapine induction of ERK1", 2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs, 2012, pp.15, 1149~1160
- Reyes-Fermín LM, "Neuroprotective effect of -mangostin and curcumin against iodoacetate-induced cell death", Nutr Neurosci, 15, pp.34~41 (2012)
- Tangpong J, "Doxorubicin-induced central nervous system toxicity and protection by xanthone derivative of Garcinia mangostana", Neuroscience, 175, pp.292~299 (2011)
- Li G, "Polyphenols from the mangosteen(Garcinia mangostana)fruit for breast and prostate cancer", Front Pharmacol, 4, pp.80~ (2013)
- Liu Z, "The effect of gartanin, a naturally occurring xanthone in mangosteen juice, on the mTOR pathway, autophagy, apoptosis, and the growth of human urinary bladder cancer cell lines", Nutr Cancer, 65(Suppl 1), pp.68~77 (2013)
- Huang HJ, "Multifunctional effects of mangosteen pericarp on cognition in C57BL", 6J and triple transgenic Alzheimer's mice, 2014, pp.2014, 813672~
- Oberholzer I, "Garcinia mangostana Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression : a bio-behavioral study in the Flinders Sensitive Line rat", Metab Brain Dis, 33, pp.467~480 (2018)
- Kay SR, "The Positive and Negative Syndrome Scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Therapeutic Goods Administration, "The Australian clinical trial handbook", Department of Health and Ageing, Australian Government, ~ (2006)
- National Health and Medical Research Council, "National Statement on Ethical Conduct in Human Research 2007 (updated May 2015)", National Health and Medical Research Council, Australian Government, ~ (2007)
- Chan AW, "SPIRIT 2013 statement : defining standard protocol items for clinical trials", Ann Int Med, 158, pp.200~207 (2013)
- Schulz KF, "CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials", BMJ, 340, pp.c332~ (2010)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders. 5th ed" (2013), American Psychiatric Association
- Guy W, "ECDEU Assessment Manual for Psychopharmacology", U.S. Department of Health, Education, and Welfare, ~ (1976)
- Laupu WK, "Efficacy of Garcinia mangostana L. (mangosteen) pericarp as an adjunctive to second-generation antipsychotics for the treatment of schizophrenia: a double blind, randomised, placebo-controlled trial", pp.2014
- Kay SR, "The Positive and Negative Syndrome Scale(PANSS) : rationale and standardisation", Br J Psychiatry Suppl, pp.59~67 (1989)
- Peralta V, "Psychometric properties of the Positive and Negative Syndrome Scale(PANSS)in schizophrenia", Psychiatry Res, 53, pp.31~40 (1994)
- Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
- Endicott J, "Quality of life enjoyment and satisfaction questionnaire : a new measure", Psychopharmacol Bull, 29, pp.321~326 (1993)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: primary care version" (1994), American Psychiatric Association
- Leon AC, "A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. Longitudinal interval follow-up evaluation-range impaired functioning tool", J Nerv Ment Dis, 188, pp.805~812 (2000)
- Maruff P, "Validity of the CogState brief battery : relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex", Arch Clin Neuropsychol, 24, pp.165~178 (2009)
- Castle DJ, "The diagnostic interview for psychoses(DIP) : development, reliability and applications", Psychol Med, 36, pp.69~80 (2006)
- Craig CL, "International physical activity questionnaire : 12-country reliability and validity", Med Sci Sports Exerc, 35, pp.1381~1395 (2003)
- Harris PA, "Research electronic data capture(REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support", J Biomed Inform, 42, pp.377~381 (2009)
- Kemmler G, "Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs : a meta-analysis", Arch Gen Psychiatry, 62, pp.1305~1312 (2005)